Cross-border business development in medtech is rarely a straight line. Between regulatory complexity, reimbursement variability, cultural nuances, and market-specific needs, expanding into new regions requires more than a product—it demands a strategy. At a recent LSI medtech conference in Europe, panelists Eliane Schutte (Xeltis), Jeffrey Sirek (PRIA Healthcare), Pieter Wijffels (NLC Health Ventures), and Sabine Kapasi (Enira Consulting), led by moderator Ajay Nair (The Mullings Group), tackled the topic head-on. Drawing from firsthand experience across Europe, the United States, China, India, and the Middle East, they explored what it takes to succeed in cross-border business development—from diligence and IP to commercialization, licensing, and culture. Visit here for more details: https://www.lsieuropesummit.com/news/the-art-and-science-of-cross-border-business-development
Comments
Post a Comment